Richard Steckley, MD
Cardiovascular Disease · Wichita, KSNPI 1689637092
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,149 of the $7,781 with a category attached, or 79.0%. 34 manufacturers reported payments, led by Penumbra, Inc. at 26.0% of the total. Reporting peaked in 2022 at $2,865 and has fallen 81.0% since, to $543 in 2025.
Across 224 payments — averaging $34.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Edwards Lifesciences$842
- Abbott$717
- Medtronic$656
- AstraZeneca$611
- Novartis$523
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,40918%
- Food & beverage$6,14979%
- Education$2223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 7 | $2,025 |
| Edwards Lifesciences | 11 | $842 |
| Abbott | 13 | $717 |
| Medtronic(2 entities) | 15 | $656 |
| AstraZeneca | 22 | $611 |
| Novartis | 31 | $523 |
| Merck | 19 | $379 |
| Amgen | 20 | $301 |
| E.r. Squibb & Sons, L.L.C. | 13 | $223 |
| Sanofi-aventis U.S. LLC | 7 | $194 |
| Actelion Pharmaceuticals US, Inc. | 5 | $170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $141 |
| Inari Medical, Inc. | 1 | $120 |
| Cvrx, Inc. | 1 | $87 |
| Pfizer | 7 | $87 |
| Novo Nordisk | 4 | $78 |
| Gilead | 4 | $64 |
| Amarin Pharma, Inc. | 4 | $62 |
| Boehringer Ingelheim | 4 | $57 |
| Lemaitre Vascular, Inc. | 3 | $56 |
| Boston Scientific | 4 | $53 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Coala Life Inc | 1 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Abiomed | 1 | $25 |
| Shockwave Medical, Inc | 1 | $24 |
| Heartflow, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Bayer | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,781 in reported general payments places this provider in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,092 | $841,760 |
| XareltoRivaroxaban | 337 | $251,338 |
| EntrestoSacubitril/Valsartan | 171 | $166,487 |
| Repatha SureclickEvolocumab | 81 | $83,126 |
| MultaqDronedarone Hcl | 62 | $56,596 |
| VerquvoVericiguat | 44 | $35,433 |
| VascepaIcosapent Ethyl | 69 | $28,862 |
| BrilintaTicagrelor | 44 | $24,176 |
| Praluent PenAlirocumab | 24 | $24,176 |
| Ranolazine ErRanolazine | 217 | $16,133 |
| JardianceEmpagliflozin | 21 | $15,917 |
| FarxigaDapagliflozin Propanediol | 16 | $14,374 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 559 | $12,127 |
| Potassium Chloride | 566 | $10,838 |
| Metoprolol Succinate | 957 | $9,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $841,7601,092 claims |
| Johnson & JohnsonXarelto | $16 | $251,338337 claims |
| NovartisEntresto | $523 | $166,487171 claims |
| Sanofi-aventis U.S. LLCMultaq | $194 | $56,59662 claims |
| AstraZenecaBrilinta, Farxiga | $611 | $38,55060 claims |
| MerckVerquvo | $379 | $35,43344 claims |
| Boehringer IngelheimJardiance | $57 | $15,91721 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $41 | $5,57219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.